In the Claims:

- 1-43. (canceled).
- 44. (Currently amended) An isolated polypeptide comprising:
- (a) the amino acid sequence of the polypeptide of SEQ ID NO: 263 shown in Figure 98 (SEQ ID NO: 263);
- (b) the amino acid sequence of the polypeptide of SEQ ID NO: 263 shown in Figure 98 (SEQ ID NO: 263), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide of SEQ ID NO: 263 shown in Figure 98 (SEQ ID NO:263);
- (d) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209481; wherein, the nucleic acid encoding said polypeptide is amplified in lung or colon tumors.
- 45. (Currently amended) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide of SEQ ID NO: 263 shown in Figure 98 (SEQ ID NO:263).
- 46. (Currently amended) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide of SEQ ID NO: 263 shown in Figure 98 (SEQ ID NO: 263), lacking its associated signal peptide.
- 47. (Currently amended) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the extracellular domain of the polypeptide of SEQ ID NO: 263 shown in Figure 98 (SEQ ID NO:263).
- 48. (canceled).
- 49. (Previously presented) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209481.

- 50. (Previously presented) A chimeric polypeptide comprising a polypeptide according to Claim 44 fused to a heterologous polypeptide.
- 51. (Previously presented) The chimeric polypeptide of Claim 50, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.